Clovis Oncology Inc (CLVS.OQ) Quote| Reuters.com
Edition:
United States

Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

14.69USD
4:00pm EDT
Change (% chg)

$0.97 (+7.07%)
Prev Close
$13.72
Open
$13.65
Day's High
$15.12
Day's Low
$13.47
Volume
509,970
Avg. Vol
400,237
52-wk High
$116.75
52-wk Low
$11.57

CLVS.OQ

Chart for CLVS.OQ

About

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth... (more)

Overall

Beta: 2.17
Market Cap(Mil.): $526.65
Shares Outstanding(Mil.): 38.39
Dividend: --
Yield (%): --

Financials

  CLVS.OQ Industry Sector
P/E (TTM): -- 42.29 36.15
EPS (TTM): -10.01 -- --
ROI: -61.18 -6.23 14.31
ROE: -153.78 -5.61 15.51

UPDATE 2-Tesaro's ovarian cancer drug study succeeds, shares soar

* Shares of rival Clovis Oncology also rise (Adds details; analyst comments)

Jun 29 2016

BRIEF-Clovis Oncology Inc files for mixed shelf of up to $200 mln

* Clovis Oncology Inc files for mixed shelf of up to $200 million Source text: http://1.usa.gov/1XdI04i Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jun 10 2016

BRIEF-Clovis Oncology presents data from phase 2 studies of rucaparib

* Nineteen patients (9%) discontinued treatment because of an adverse event.

Jun 06 2016

BRIEF-Clovis Oncology reports Q1 loss per share $2.17

* Clovis oncology announces q1 2016 operating results and corporate update

May 05 2016

FDA panel votes against approving Clovis's cancer drug on current data

An independent panel of experts advising the U.S. Food and Drug Administration recommended that Clovis Oncology Inc's lung cancer drug not be approved based on existing trial data.

Apr 12 2016

UPDATE 2-FDA panel votes against approving Clovis's cancer drug on current data

* Shares fall as much as 18.7 percent (Adds detail, comments from company, analyst)

Apr 12 2016

CORRECTED-UPDATE 1-FDA panel votes against quick approval for Clovis cancer drug

April 12 An independent panel of experts advising the U.S. Food and Drug Administration did not back the accelerated approval of Clovis Oncology Inc's lung cancer drug.

Apr 12 2016

FDA staff casts doubt on Clovis' lung cancer drug

U.S. Food and Drug Administration staff members on Friday questioned whether Clovis Oncology Inc's lung cancer drug was superior to existing treatments and also raised concerns about its safety profile.

Apr 08 2016

UPDATE 2-FDA staff casts doubt on Clovis' lung cancer drug

* Shares fall 5 pct in choppy trading (Adds analyst comment; updates shares)

Apr 08 2016

BRIEF-Clovis Oncology VP Daniel Muehl appointed as principal financial officer and principal accounting officer

* Daniel Muehl, co's vice president of finance, appointed as company's principal financial officer and principal accounting officer Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Apr 01 2016

Competitors

  Price Chg
Eisai Co., Ltd (4523.T) ¥5,795 +107.00
Pfizer Inc. (PFE.N) $35.57 +0.36
AstraZeneca plc (AZN.L) 4,502.50p +35.50
BioMarin Pharmaceutical Inc. (BMRN.OQ) $81.38 +3.58
TESARO Inc (TSRO.OQ) $81.06 -2.99
AbbVie Inc (ABBV.N) $62.71 +0.80
Novartis AG (NOVN.S) CHF80.45 +0.30
Johnson & Johnson (JNJ.N) $121.29 -0.01
Eli Lilly and Co (LLY.N) $78.95 +0.20
GlaxoSmithKline plc (GSK.L) 1,600.00p -4.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.